> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Lifts Marker Therapeutics Phase 2 Trial Partial Hold
- URL: https://www.fdaweb.com/fda-lifts-marker-therapeutics-phase-2-trial-partial-hold/
- Published: 2021-01-05T12:00:00.000Z
- Updated: 2026-09-14T16:41:21.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148378

FDA has lifted its partial hold on a Marker Therapeutics Phase 2 trial investigating the safety and efficacy of MAT-401, the company’s lead multi-tumor-associated antigen-specific T cell product candidate for treating post-transplant acute myeloid leukemia (AML). The company [says](https://finance.yahoo.com/news/marker-therapeutics-announces-fda-lifted-120000425.html?ref=fdaweb.com) the trial is evaluating the clinical efficacy of MT-401 in patients with AML in both the adjuvant and active disease setting following an allogeneic stem cell transplant. The trial’s primary objectives are to evaluate relapse-free survival in the adjuvant group and determine the complete remission rate and duration of complete remission in active disease patients, the company says.